PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-51.66%
Revenue decline while VET shows 20.00% growth. Joel Greenblatt would examine competitive position erosion.
-5.04%
Cost reduction while VET shows 3.14% growth. Joel Greenblatt would examine competitive advantage.
-93.69%
Gross profit decline while VET shows 82.61% growth. Joel Greenblatt would examine competitive position.
-86.94%
Margin decline while VET shows 52.18% expansion. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
-12.36%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
-127.59%
Other expenses reduction while VET shows 133.33% growth. Joel Greenblatt would examine efficiency.
-14.04%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-10.41%
Both companies reducing total costs. Martin Whitman would check industry trends.
3.88%
Interest expense growth while VET reduces costs. John Neff would investigate differences.
-11.88%
D&A reduction while VET shows 4.77% growth. Joel Greenblatt would examine efficiency.
-131.33%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
-2.96%
EBITDA margin decline while VET shows 52.00% growth. Joel Greenblatt would examine position.
-226.72%
Operating income decline while VET shows 59.29% growth. Joel Greenblatt would examine position.
-575.87%
Operating margin decline while VET shows 66.08% growth. Joel Greenblatt would examine position.
-142.98%
Other expenses reduction while VET shows 46.33% growth. Joel Greenblatt would examine advantage.
-57.06%
Both companies show declining income. Martin Whitman would check industry conditions.
-224.90%
Both companies show margin pressure. Martin Whitman would check industry conditions.
-55.15%
Both companies reducing tax expense. Martin Whitman would check patterns.
-58.58%
Net income decline while VET shows 35.12% growth. Joel Greenblatt would examine position.
-228.04%
Net margin decline while VET shows 45.93% growth. Joel Greenblatt would examine position.
-57.78%
EPS decline while VET shows 36.84% growth. Joel Greenblatt would examine position.
-58.74%
Diluted EPS decline while VET shows 36.84% growth. Joel Greenblatt would examine position.
0.51%
Share count reduction exceeding 1.5x VET's 2.34%. David Dodd would verify capital allocation.
No Data
No Data available this quarter, please select a different quarter.